Finding the best PrEP doses for pregnant women in sub-Saharan Africa

Optimizing PrEP regimens for pregnant women in sub-Saharan Africa

NIH-funded research Univ of North Carolina Chapel Hill · NIH-11077771

This study is looking at the best way to give HIV prevention medication to pregnant women in sub-Saharan Africa to help keep them safe from HIV, and it will involve trying different doses during their pregnancy and checking how well it works and how safe it is afterward.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniv of North Carolina Chapel Hill NIH-funded
Lab location1 site (Chapel Hill, United States)
Project IDNIH-11077771 on NIH RePORTER

What this research studies

This research investigates how to optimize the dosing of pre-exposure prophylaxis (PrEP) medication for pregnant women in sub-Saharan Africa to effectively reduce the risk of HIV acquisition. The study will involve pregnant women who will be given different doses of the medication during their second and third trimesters, followed by a postpartum evaluation. By measuring drug levels in the blood and assessing safety outcomes, the research aims to determine the most effective dosing strategy for this vulnerable population.

Who could benefit from this research

Good fit: Ideal candidates for this research are pregnant women in their second or third trimester living in sub-Saharan Africa.

Not a fit: Patients who are not pregnant or those who are not at risk of HIV acquisition may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved PrEP dosing guidelines that enhance HIV prevention for pregnant women.

How similar studies have performed: Previous research has shown that optimizing medication dosing can significantly improve treatment outcomes, suggesting potential success for this approach.

Where this research is happening

Chapel Hill, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.